Key Quantitative Figures
- Investment amount: ₹199,99,99,995 (Rupees one hundred and ninety-nine crore ninety-nine lakh ninety-nine thousand nine hundred and ninety-five only)
- Number of shares allotted: 5,71,42,857 equity shares of ₹10 each at a premium of ₹25 per share
- Total investment in EESL to date: ₹5,102.23 crore
- EESL's paid-up equity share capital as on date: ₹1,589.93 crore
- EESL's net worth as on 31.03.2026: ₹3,991.06 crore
- EESL's turnover for FY 2025-26: ₹157.56 crore
- EESL's loss after tax for FY 2025-26: ₹248.16 crore
Dates of Action
- Board approval date: 30th January 2026
- Investment execution date: 18th August 2026
- Share allotment date: 18th August 2026
- EESL incorporation date: 24th March 2022
Parties Involved
- Exide Industries Limited (Investor)
- Exide Energy Solutions Limited (Recipient, wholly owned subsidiary)
- Regulatory authorities: SEBI, BSE Limited, National Stock Exchange of India Limited, The Calcutta Stock Exchange Limited
Purpose and Rationale
The investment is to fund EESL's green field multi-gigawatt lithium-ion cell manufacturing facility in Bengaluru, India. The facility will manufacture battery cells of advanced chemistry and form factor (cylindrical, pouch, prismatic) as well as battery modules and packs for India's electric vehicle market and stationary applications.
Ownership Impact
- No change in shareholding percentage: Exide Industries maintains 100% ownership in EESL
- The investment was made on a rights basis
- Total investment includes investment made in erstwhile merged subsidiary Exide Energy Private Limited (EEPL)
Transaction Details
- Nature of consideration: Cash
- Type of transaction: Related party transaction (wholly owned subsidiary)
- Transaction executed at arm's length
- No governmental or regulatory approvals required
Subsidiary Financial Performance
EESL's turnover for the last three years:
- FY 2025-26: ₹157.56 crore
- FY 2024-25: ₹116.89 crore* (subsequent to merger of EEPL with EESL)
- FY 2023-24: ₹239.14 crore* (subsequent to merger of EEPL with EESL)
Capital Structure Context
The investment is part of the ₹1400 crore capital infusion approved by the Board of Directors on 30th January 2026, which may be executed in one or more tranches.